Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTH NASDAQ:DRTS NASDAQ:PDEX NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.35+8.5%$10.90$8.35▼$18.23$397.03M0.84588,104 shs848,173 shsDRTSAlpha Tau Medical$3.93+4.0%$3.67$2.12▼$4.69$333.34M1.0763,448 shs21,076 shsPDEXPro-Dex$26.52-20.4%$39.40$24.22▼$70.26$86.99M-0.1146,814 shs488,890 shsTMCITreace Medical Concepts$6.00+2.0%$6.80$4.54▼$10.79$379.02M0.69380,544 shs288,726 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems0.00%-5.77%-3.51%-11.88%+25.65%DRTSAlpha Tau Medical0.00%-12.30%-0.79%+17.03%+71.82%PDEXPro-Dex0.00%-2.06%+0.79%-27.90%+13.41%TMCITreace Medical Concepts0.00%-7.55%-18.56%-1.84%+11.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.35+8.5%$10.90$8.35▼$18.23$397.03M0.84588,104 shs848,173 shsDRTSAlpha Tau Medical$3.93+4.0%$3.67$2.12▼$4.69$333.34M1.0763,448 shs21,076 shsPDEXPro-Dex$26.52-20.4%$39.40$24.22▼$70.26$86.99M-0.1146,814 shs488,890 shsTMCITreace Medical Concepts$6.00+2.0%$6.80$4.54▼$10.79$379.02M0.69380,544 shs288,726 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems0.00%-5.77%-3.51%-11.88%+25.65%DRTSAlpha Tau Medical0.00%-12.30%-0.79%+17.03%+71.82%PDEXPro-Dex0.00%-2.06%+0.79%-27.90%+13.41%TMCITreace Medical Concepts0.00%-7.55%-18.56%-1.84%+11.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 2.80Moderate Buy$24.50117.37% UpsideDRTSAlpha Tau Medical 2.00Hold$9.00130.47% UpsidePDEXPro-Dex 2.50Moderate Buy$56.00108.16% UpsideTMCITreace Medical Concepts 2.14Hold$9.8365.68% UpsideCurrent Analyst Ratings BreakdownLatest PDEX, TMCI, DCTH, and DRTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DCTHDelcath SystemsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025DRTSAlpha Tau MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PDEXPro-DexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025TMCITreace Medical ConceptsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DCTHDelcath SystemsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025DRTSAlpha Tau MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PDEXPro-DexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025TMCITreace Medical ConceptsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/4/2025TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$6.60 ➝ $8.009/3/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/8/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$8.60 ➝ $6.50(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$70.24M5.61N/AN/A$2.15 per share5.24DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/APDEXPro-Dex$66.59M1.33$2.53 per share10.63$11.23 per share2.40TMCITreace Medical Concepts$209.36M1.79N/AN/A$1.81 per share3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M$0.05224.90N/AN/A3.18%6.91%5.80%11/14/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.48N/AN/AN/AN/A-51.21%-38.18%11/18/2025 (Estimated)PDEXPro-Dex$8.98M$2.7010.2113.06N/A13.48%26.67%14.95%10/30/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.79N/AN/AN/A-23.01%-46.76%-23.35%11/4/2025 (Estimated)Latest PDEX, TMCI, DCTH, and DRTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025TMCITreace Medical Concepts-$0.28N/AN/AN/A$49.60 millionN/A10/30/2025Q1 2026PDEXPro-Dex$0.50N/AN/AN/A$15.30 millionN/A9/4/2025Q4 2025PDEXPro-Dex$0.47$0.36-$0.11$0.36$17.90 million$17.49 million8/11/2025Q2 2025DRTSAlpha Tau Medical-$0.12-$0.13-$0.01-$0.13N/AN/A8/7/2025Q2 2025TMCITreace Medical Concepts-$0.29-$0.28+$0.01-$0.28$47.08 million$47.39 million8/6/2025Q2 2025DCTHDelcath Systems$0.02$0.07+$0.05$0.07$22.84 million$24.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A10.889.87DRTSAlpha Tau Medical0.0710.525.81PDEXPro-Dex0.253.231.71TMCITreace Medical Concepts0.553.522.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%DRTSAlpha Tau Medical2.65%PDEXPro-Dex15.28%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%DRTSAlpha Tau Medical39.50%PDEXPro-Dex47.50%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.98 million28.71 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataPDEXPro-Dex1403.28 million1.77 millionNot OptionableTMCITreace Medical Concepts25063.17 million45.66 millionOptionablePDEX, TMCI, DCTH, and DRTS HeadlinesRecent News About These CompaniesLake Street Sticks to Their Buy Rating for Treace Medical Concepts (TMCI)October 12 at 5:54 PM | theglobeandmail.comBTIG Reaffirms Their Buy Rating on Treace Medical Concepts (TMCI)October 12 at 5:54 PM | theglobeandmail.comWeiss Ratings Reiterates Sell (E+) Rating for Treace Medical Concepts (NASDAQ:TMCI)October 9, 2025 | marketbeat.comTreace Medical Concepts, Inc. $TMCI Shares Purchased by Gagnon Securities LLCOctober 8, 2025 | marketbeat.comGagnon Advisors LLC Raises Position in Treace Medical Concepts, Inc. $TMCIOctober 8, 2025 | marketbeat.comTreace Medical Concepts Insider Ups Holding During YearSeptember 21, 2025 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Rating of "Hold" by AnalystsSeptember 20, 2025 | marketbeat.comAcadian Asset Management LLC Increases Holdings in Treace Medical Concepts, Inc. $TMCISeptember 18, 2025 | marketbeat.comTreace Medical Concepts, Inc.: Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual ...September 10, 2025 | finanznachrichten.deTreace Medical to highlight product innovations, data for ALIGN3D, MTA3DSeptember 10, 2025 | msn.comTreace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual MeetingSeptember 10, 2025 | globenewswire.comTreace Medical Concepts, Inc. (TMCI) Investor Day 2025 Call TranscriptSeptember 3, 2025 | seekingalpha.comTreace Medical Concepts: Positive Q2 Earnings Call HighlightsAugust 12, 2025 | tipranks.comAnalysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest ReportAugust 12, 2025 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comTreace Medical Concepts Inc (TMCI) Q2 2025 Earnings Call Highlights: Revenue Growth and ...August 8, 2025 | uk.finance.yahoo.comTreace Medical anticipates 7–10% revenue growth in 2025 while launching next-gen bunion solutionsAugust 8, 2025 | msn.comTreace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comTreace Medical (TMCI) Q2 Revenue Up 7%August 7, 2025 | fool.comTreace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comTreace Medical Concepts Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDEX, TMCI, DCTH, and DRTS Company DescriptionsDelcath Systems NASDAQ:DCTH$11.35 +0.89 (+8.51%) Closing price 04:00 PM EasternExtended Trading$11.35 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Alpha Tau Medical NASDAQ:DRTS$3.93 +0.15 (+3.97%) Closing price 04:00 PM EasternExtended Trading$3.93 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Pro-Dex NASDAQ:PDEX$26.52 -6.81 (-20.43%) Closing price 04:00 PM EasternExtended Trading$26.41 -0.11 (-0.41%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Treace Medical Concepts NASDAQ:TMCI$6.00 +0.12 (+2.04%) Closing price 04:00 PM EasternExtended Trading$6.00 +0.00 (+0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
